{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T10:28:45Z","timestamp":1773656925199,"version":"3.50.1"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T00:00:00Z","timestamp":1531958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,1]]},"DOI":"10.1093\/ajcp\/aqy064","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T23:17:23Z","timestamp":1527031043000},"page":"421-431","source":"Crossref","is-referenced-by-count":14,"title":["A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow"],"prefix":"10.1093","volume":"150","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-5959","authenticated-orcid":false,"given":"Hong","family":"Fang","sequence":"first","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhett P","family":"Ketterling","sequence":"additional","affiliation":[{"name":"Division of Laboratory Genetics and Genomics, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis A","family":"Hanson","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J","family":"Kurtin","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia T","family":"Greipp","sequence":"additional","affiliation":[{"name":"Division of Laboratory Genetics and Genomics, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew T","family":"Howard","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca L","family":"King","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel L","family":"Van Dyke","sequence":"additional","affiliation":[{"name":"Division of Laboratory Genetics and Genomics, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaaren K","family":"Reichard","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,7,19]]},"reference":[{"key":"key\n\t\t\t\t20181001110222_CIT0001","volume-title":"Bone Marrow Pathology","author":"Foucar","year":"2010","edition":"3rd ed"},{"key":"key\n\t\t\t\t20181001110222_CIT0002","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","article-title":"Myeloid neoplasms with eosinophilia","volume":"129","author":"Reiter","year":"2017","journal-title":"Blood"},{"key":"key\n\t\t\t\t20181001110222_CIT0003","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"key\n\t\t\t\t20181001110222_CIT0004","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2141.2006.06038.x","article-title":"Eosinophilia: secondary, clonal and idiopathic","volume":"133","author":"Tefferi","year":"2006","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20181001110222_CIT0005","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/bjh.14488","article-title":"Guideline for the investigation and management of eosinophilia","volume":"176","author":"Butt","year":"2017","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20181001110222_CIT0006","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.path.2013.08.008","article-title":"The differential diagnosis of eosinophilia in neoplastic hematopathology","volume":"6","author":"Johnson","year":"2013","journal-title":"Surg Pathol Clin"},{"key":"key\n\t\t\t\t20181001110222_CIT0007","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017","edition":"4th ed"},{"key":"key\n\t\t\t\t20181001110222_CIT0008","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/ajh.24196","article-title":"World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management","volume":"90","author":"Gotlib","year":"2015","journal-title":"Am J Hematol"},{"key":"key\n\t\t\t\t20181001110222_CIT0009","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0145-2126(02)00046-2","article-title":"Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate","volume":"26","author":"Ault","year":"2002","journal-title":"Leuk Res"},{"key":"key\n\t\t\t\t20181001110222_CIT0010","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181001110222_CIT0011","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2003-01-0081","article-title":"Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"key\n\t\t\t\t20181001110222_CIT0012","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1038\/leu.2014.168","article-title":"ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant","volume":"28","author":"Falchi","year":"2014","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t20181001110222_CIT0013","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","article-title":"FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"key":"key\n\t\t\t\t20181001110222_CIT0014","first-page":"871","article-title":"FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia","volume":"89","author":"Tefferi","year":"2004","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t20181001110222_CIT0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40364-016-0070-7","article-title":"A novel three-way rearrangement involving ETV6 (12p13) and ABL1 (9q34) with an unknown partner on 3p25 resulting in a possible ETV6-ABL1 fusion in a patient with acute myeloid leukemia: a case report and a review of the literature","volume":"4","author":"Tirado","year":"2016","journal-title":"Biomark Res"},{"key":"key\n\t\t\t\t20181001110222_CIT0016","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/sj.leu.2404266","article-title":"FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation","volume":"20","author":"Vu","year":"2006","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t20181001110222_CIT0017","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-03-343426","article-title":"Response of ETV6-FLT3-positive myeloid\/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3","volume":"118","author":"Walz","year":"2011","journal-title":"Blood"},{"key":"key\n\t\t\t\t20181001110222_CIT0018","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3324\/haematol.2016.144345","article-title":"Characterization of leukemias with ETV6-ABL1 fusion","volume":"101","author":"Zaliova","year":"2016","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t20181001110222_CIT0019","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00277-013-1843-9","article-title":"Successful allogeneic stem cell transplantation with long-term remission of ETV6\/FLT3-positive myeloid\/lymphoid neoplasm with eosinophilia","volume":"93","author":"Chonabayashi","year":"2014","journal-title":"Ann Hematol"},{"key":"key\n\t\t\t\t20181001110222_CIT0020","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.exphem.2007.07.002","article-title":"A constitutively active Sptbn1-Flt3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy","volume":"35","author":"Grand","year":"2007","journal-title":"Exp Hematol"},{"key":"key\n\t\t\t\t20181001110222_CIT0021","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.3324\/haematol.2017.165340","article-title":"Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome","volume":"102","author":"Wang","year":"2017","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t20181001110222_CIT0022","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"key\n\t\t\t\t20181001110222_CIT0023","volume-title":"An International System for Human Cytogenetic Nomenclature (2009) Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature","author":"Shaffer","year":"2009"},{"key":"key\n\t\t\t\t20181001110222_CIT0024","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1309\/2VQLDHVJB9YW83KB","article-title":"Isolated trisomy 15: a clonal chromosome abnormality in bone marrow with doubtful hematologic significance","volume":"129","author":"Hanson","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"key\n\t\t\t\t20181001110222_CIT0025","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.leukres.2011.05.002","article-title":"The significance of isolated Y chromosome loss in bone marrow metaphase cells from males over age 50 years","volume":"35","author":"Wiktor","year":"2011","journal-title":"Leuk Res"},{"key":"key\n\t\t\t\t20181001110222_CIT0026","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of Pcr primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the Biomed-2 concerted action Bmh4-Ct98-3936","volume":"17","author":"van Dongen","year":"2003","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t20181001110222_CIT0027","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cancergencyto.2004.01.013","article-title":"Prevalence, breakpoint distribution, and clinical correlates of t(5;12)","volume":"153","author":"Greipp","year":"2004","journal-title":"Cancer Genet Cytogenet"},{"key":"key\n\t\t\t\t20181001110222_CIT0028","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)08505-7","article-title":"Treatment of hypereosinophilic syndrome with imatinib mesilate","volume":"359","author":"Gleich","year":"2002","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20181001110222_CIT0029","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaip.2017.06.006","article-title":"Hypereosinophilic syndrome subtype predicts responsiveness to glucocorticoids","volume":"6","author":"Khoury","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"key\n\t\t\t\t20181001110222_CIT0030","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","article-title":"How I treat hypereosinophilic syndromes","volume":"126","author":"Klion","year":"2015","journal-title":"Blood"},{"key":"key\n\t\t\t\t20181001110222_CIT0031","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"key\n\t\t\t\t20181001110222_CIT0032","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4269\/ajtmh.2008.78.702","article-title":"Eosinophilia among returning travelers: a practical approach","volume":"78","author":"Meltzer","year":"2008","journal-title":"Am J Trop Med Hyg"},{"key":"key\n\t\t\t\t20181001110222_CIT0033","first-page":"15","article-title":"Hypereosinophilic syndrome due to ETV6\/PDGFR-beta gene translocation\u2014a diagnostic and therapeutic challenge","volume":"47","author":"Morais Silva","year":"2015","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"key\n\t\t\t\t20181001110222_CIT0034","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00277-013-1695-3","article-title":"Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1","volume":"92","author":"Patterer","year":"2013","journal-title":"Ann Hematol"},{"key":"key\n\t\t\t\t20181001110222_CIT0035","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.hoc.2017.04.009","article-title":"Tyrosine kinase inhibitors in the treatment of eosinophilic neoplasms and systemic mastocytosis","volume":"31","author":"Gotlib","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"key":"key\n\t\t\t\t20181001110222_CIT0036","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.leukres.2011.05.006","article-title":"Tyrosine kinase inhibitors in the treatment of systemic mastocytosis","volume":"35","author":"Ustun","year":"2011","journal-title":"Leuk Res"},{"key":"key\n\t\t\t\t20181001110222_CIT0037","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/ejh.12043","article-title":"Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression","volume":"90","author":"Verstovsek","year":"2013","journal-title":"Eur J Haematol"},{"key":"key\n\t\t\t\t20181001110222_CIT0038","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome\u2013negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t20181001110222_CIT0039","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.5858\/arpa.2016-0223-RA","article-title":"Blood and bone marrow evaluation for eosinophilia","volume":"140","author":"Boyer","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"key\n\t\t\t\t20181001110222_CIT0040","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.iac.2007.07.002","article-title":"Lymphocytic variant hypereosinophilic syndromes","volume":"27","author":"Roufosse","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"key\n\t\t\t\t20181001110222_CIT0041","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1038\/leu.2017.240","article-title":"Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia","volume":"31","author":"Jawhar","year":"2017","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t20181001110222_CIT0042","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.ejim.2016.02.024","article-title":"Imatinib mesylate for unmutated hypereosinophilic syndromes: does it work","volume":"32","author":"Helbig","year":"2016","journal-title":"Eur J Intern Med"},{"key":"key\n\t\t\t\t20181001110222_CIT0043","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s12032-011-9831-1","article-title":"Imatinib mesylate may induce long-term clinical response in FIP1L1-pdgfr\u03b1-negative hypereosinophilic syndrome","volume":"29","author":"Helbig","year":"2012","journal-title":"Med Oncol"},{"key":"key\n\t\t\t\t20181001110222_CIT0044","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/modpathol.2016.75","article-title":"Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified","volume":"29","author":"Wang","year":"2016","journal-title":"Mod Pathol"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajcp\/article-pdf\/150\/5\/421\/25883249\/aqy064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T06:10:04Z","timestamp":1571379004000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/150\/5\/421\/5056049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,19]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,7,19]]},"published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqy064","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,11]]},"published":{"date-parts":[[2018,7,19]]}}}